September 17, 2021
A shareholder in Myriad Genetics Inc. told a Delaware federal court that company executives and directors lied to investors for years about a study of one of its flagship products, a genetic test intended to predict a patient's response to drugs for pain relief, ADHD and depression, according to the derivative suit filed Friday.